Updates on Sexually Transmitted Infections: Gonorrhea, Chlamydia, and Syphilis Testing and Treatment in the Emergency Department

  • Sharon TangEmail author
Infectious Disease (J Glauser, Section Editor)
Part of the following topical collections:
  1. Infectious Disease


Purpose of Review

This review describes current guidelines and research on screening, diagnostics, and treatment for sexually transmitted infections (STIs) seen in the emergency department (ED).

Recent Findings

Many studies support less invasive testing for STIs, which in turn would encourage increased screening. The diagnosis of pelvic inflammatory disease (PID) is currently based on clinical findings and further research is needed to improve diagnostic accuracy. Current antibiotic treatment guidelines are based on numerous studies. Drug-resistant gonorrhea is an issue worldwide and alternative treatments are currently being evaluated.


Highly sensitive testing has allowed for noninvasive screening. Increased screening in the ED would identify more infections and potentially prevent complications of untreated infections. Diagnosis of PID still requires a full pelvic examination given that diagnosis is based on exam findings. Antibiotic resistance is on the rise and treatment guidelines should be strictly followed. Future vaccine and novel antibiotics are currently in randomized control trials.


Sexually transmitted infection Emergency department screening Gonorrhea resistance Syphilis screening 


Compliance With Ethical Standards

Conflict of Interest

The author declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    CDC. Sexually Transmitted Disease Surveillance 2016. US Dep Heal Hum Serv. 2017.Google Scholar
  2. 2.
    Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. 2003;36:502–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2015:2015.Google Scholar
  4. 4.
    Shepherd, Suzanne M et. al. Pelvic inflammatory disease. Tintinalli’s emergency medicine: a comprehensive study guide 8e. 8th ed. Judith E Tintinalli et. al., editor. NY: McGraw Hill; 2016.Google Scholar
  5. 5.
    WHO. WHO Guidelines for the Treatment of Chlamydia trachomatis. Who [Internet]. 2016;340:c2637–c2637. Available from:
  6. 6.
    Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61–77.CrossRefPubMedGoogle Scholar
  7. 7.
    Sexton J, Garnett G, Røttingen J-A. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis. 2005;32:351–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35:946–59.CrossRefPubMedGoogle Scholar
  9. 9.
    LeFevre ML. Screening for Chlamydia and Gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:902–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Schneider K, Fitzgerald M, Byczkowski T, Reed J. Screening for asymptomatic gonorrhea and chlamydia in the pediatric emergency department. Sex Transm Dis. 2016;43:209–15.CrossRefPubMedGoogle Scholar
  11. 11.
    • Low N, Redmond S, Uusküla A, van Bergen J, Ward H, Andersen B, Götz H, Cochrane STI Group. Screening for genital chlamydia infection. Cochrane Database Syst Rev. 2016. Review of data regarding impact of chlamydia screening. Google Scholar
  12. 12.
    Shafer MA, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med. 1999;153:119–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Shih SL, Graseck AS, Secura GM, Peipert JF. Screening for sexually transmitted infections at home or in the clinic? Curr Opin Infect Dis. 2011;24:78–84.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jamil MS, Hocking JS, Bauer HM, Ali H, Wand H, Smith K, et al. Home-based chlamydia and gonorrhoea screening: a systematic review of strategies and outcomes. BMC Public Health. 2013;13:189.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Odesanmi TY, Wasti SP, Odesanmi OS, Adegbola O, Oguntuase OO, Mahmood S. Comparative effectiveness and acceptability of home-based and clinic-based sampling methods for sexually transmissible infections screening in females aged 14–50 years: a systematic review and meta-analysis. Sex Health. 2013;10:559–69.CrossRefPubMedGoogle Scholar
  16. 16.
    Mimiaga MJ, Reisner SL, Bland S, Skeer M, Cranston K, Isenberg D, et al. Health system and personal barriers resulting in decreased utilization of HIV and STD testing services among at-risk black men who have sex with men in Massachusetts. AIDS Patient Care STDs. 2009;23:825–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Landovitz RJ, Gildner JL, Leibowitz AA. Sexually transmitted infection testing of HIV-positive Medicare and Medicaid enrollees falls short of guidelines. Sex Transm Dis. 2018;45:8–13.PubMedGoogle Scholar
  18. 18.
    Berry SA, Ghanem KG, Page KR, Thio CL, Moore RD, Gebo KA. Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines. Sex Transm Infect. 2010;86:481–4.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep. 2014;63:1–19.Google Scholar
  20. 20.
    Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008;35:637–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Bachmann LH, Johnson RE, Cheng H, Markowitz LE, Papp JR, Hook EW, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol. 2009;47:902–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bachmann LH, Johnson RE, Cheng H, Markowitz L, Papp JR, Palella FJ, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48:1827–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mimiaga MJ, Mayer KH, Reisner SL, Gonzalez A, Dumas B, Vanderwarker R, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis. 2008;35:495–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Schachter J, McCormack WM, Chernesky MA, Martin DH, Van Der Pol B, Rice PA, et al. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol. 2003;41:3784–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Shafer M-A, Moncada J, Boyer CB, Betsinger K, Flinn SD, Schachter J. Comparing first-void urine specimens, self-collected vaginal swabs, and endocervical specimens to detect Chlamydia trachomatis and Neisseria gonorrhoeae by a nucleic acid amplification test. J Clin Microbiol. 2003;41:4395–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Masek BJ, Arora N, Quinn N, Aumakhan B, Holden J, Hardick A, et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program. J Clin Microbiol. 2009;47:1663–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Schachter J, Chernesky MA, Willis DE, Fine PM, Martin DH, Fuller D, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis. 2005;32:725–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Stewart CMW, Schoeman SA, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ. 2012;345.Google Scholar
  29. 29.
    Schoeman SA, Stewart CMW, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ. 2012;345.Google Scholar
  30. 30.
    Falk L, Coble B-I, Mjörnberg P-A, Fredlund H. Sampling for Chlamydia trachomatis infection—a comparison of vaginal, first-catch urine, combined vaginal and first-catch urine and endocervical sampling. Int J STD AIDS. 2010;21:283–7.CrossRefPubMedGoogle Scholar
  31. 31.
    • Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One. 2015;10. Recent review of studies supporting less invasive specimen collection for GC and CT screening.:e0132776.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Van Der Pol B, Quinn TC, Gaydos CA, Crotchfelt K, Schachter J, Moncada J, et al. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis. J Clin Microbiol. 2000;38:1105–12.Google Scholar
  33. 33.
    Martin DH, Cammarata C, Van Der Pol B, Jones RB, Quinn TC, Gaydos CA, et al. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae. J Clin Microbiol. 2000;38:3544–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Gaydos CA, Ferrero DV, Papp J. Laboratory aspects of screening men for Chlamydia trachomatis in the new millennium. Sex Transm Dis. 2008;35:S45–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Patton ME, Kidd S, Llata E, Stenger M, Braxton J, Asbel L, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010-2012. Clin Infect Dis. 2014;58:1564–70.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 2005;41:67–74.CrossRefPubMedGoogle Scholar
  37. 37.
    Annan NT, Sullivan AK, Nori A, Naydenova P, Alexander S, McKenna A, et al. Rectal chlamydia—a reservoir of undiagnosed infection in men who have sex with men. Sex Transm Infect. 2009;85:176–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, et al. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:1–17.CrossRefGoogle Scholar
  39. 39.
    Trebach JD, Chaulk CP, Page KR, Tuddenham S, Ghanem KG. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis. 2015;42:233–9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Romero R, Espinoza J, Mazor M. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization? Fertil Steril. 2004;82:799–804.CrossRefPubMedGoogle Scholar
  41. 41.
    Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012;30:1114–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Goller JL, De Livera AM, Fairley CK, Guy RJ, Bradshaw CS, Chen MY, et al. Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: a cross-sectional analysis of routinely collected sexual health clinic data. Sex Transm Infect. 2017;93:68–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Ness RB, Kip KE, Hillier SL, Soper DE, Stamm CA, Sweet RL, et al. A cluster analysis of bacterial vaginosis–associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005;162:585–90.CrossRefPubMedGoogle Scholar
  44. 44.
    Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol. 2012;206:476.e1–8.CrossRefGoogle Scholar
  45. 45.
    Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;c1642:340.Google Scholar
  47. 47.
    Geisler WM, Chow JM, Schachter J, McCormack WM. Pelvic examination findings and Chlamydia trachomatis infection in asymptomatic young women screened with a nucleic acid amplification test. Sex Transm Dis. 2007;34:335–8.PubMedGoogle Scholar
  48. 48.
    Qaseem A, Humphrey LL, Harris R, Starkey M, Denberg TD. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161:67.CrossRefPubMedGoogle Scholar
  49. 49.
    Brown J, Fleming R, Aristzabel J, Gishta R. Does pelvic exam in the emergency department add useful information? West J Emerg Med. 2011;12:208–12.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ. Serologic response to treatment of infectious syphilis. Ann Intern Med. 1991;114:1005–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Alary M, Baganizi E, Guèdèmè A, Padonou F, Davo N, Adjovi C, et al. Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin. Sex Transm Infect. 1998;74(Suppl 1):S44–9.PubMedGoogle Scholar
  52. 52.
    Djajakusumah T, Sudigdoadi S, Keersmaekers K, Meheus A. Evaluation of syndromic patient management algorithm for urethral discharge. Sex Transm Infect. 1998;74(Suppl 1):S29–33.PubMedGoogle Scholar
  53. 53.
    Francis SC, Ao TT, Vanobberghen FM, Chilongani J, Hashim R, Andreasen A, et al. Epidemiology of curable sexually transmitted infections among women at increased risk for HIV in Northwestern Tanzania: inadequacy of syndromic management. PLoS One. 2014;9:e101221.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Mayaud P, Mabey D. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect. 2004;80:174–82.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Taylor SN, Lensing S, Schwebke J, Lillis R, Mena LA, Nelson AL, et al. Prevalence and treatment outcome of cervicitis of unknown etiology. Sex Transm Dis. 2013;40:379–85.CrossRefPubMedGoogle Scholar
  56. 56.
    Gaydos C, Maldeis NE, Hardick A, Hardick J, Quinn TC. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis. 2009;36:598–606.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Korte JE, Baseman JB, Cagle MP, Herrera C, Piper JM, Holden AEC, et al. Cervicitis and genitourinary symptoms in women culture positive for Mycoplasma genitalium. Am J Reprod Immunol. 2006;55:265–75.CrossRefPubMedGoogle Scholar
  58. 58.
    • Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17:e235–79. Review of current STI management challenges worldwide and future interventions. CrossRefPubMedGoogle Scholar
  59. 59.
  60. 60.
    WHO. WHO guidelines for the treatment of Neisseria gonorrhoeae. World Heal Organ [Internet]. 2016;1–55. Available from:
  61. 61.
    CDC. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR. 2012;61:590–4.Google Scholar
  62. 62.
    Steedman NM, McMillan A. Treatment of asymptomatic rectal Chlamydia trachomatis: is single-dose azithromycin effective? Int J STD AIDS. 2009;20:16–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal chlamydia trachomatis in men and women? Sex Transm Infect. 2012;88:352–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Kong FYS, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:1290–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Lau A, Kong F, Fairley CK, Donovan B, Chen M, Bradshaw C, et al. Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men—a double-blind randomised controlled trial protocol. BMC Infect Dis. 2017;17:35.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis. 2011;17:148–9. Centers for Disease Control and PreventionCrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273–80.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858–60.CrossRefPubMedGoogle Scholar
  69. 69.
    Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371:1850–1. Massachusetts Medical SocietyCrossRefPubMedGoogle Scholar
  70. 70.
    Lefebvre B, Martin I, Demczuk W, Deshaies L, Michaud S, Labbé A-C, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24:381–3.CrossRefPubMedCentralGoogle Scholar
  71. 71.
    Ducharme J. The First Case of Drug-Resistant Gonorrhea Was Confirmed | Time [Internet]. 2018 [cited 2018 May 25]. Available from:
  72. 72.
    Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374:2504–6. Massachusetts Medical SocietyCrossRefPubMedGoogle Scholar
  73. 73.
    Bignell C, Mb B, Frcp B, Unemo M, Professor A, Jensen JS. 2012. European guideline on the diagnosis and treatment of gonorrhoea in adults. [cited 2018 Apr 30]; Available from:
  74. 74.
    Yu R, Yin Y, Wang G, Chen S, Zheng B, Dai X, et al. Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis. Chaturvedi V, editor. PLoS One. Public Library of Science; 2014;9:e87849.Google Scholar
  75. 75.
    Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007;13:1275–7. Centers for Disease Control and PreventionPubMedPubMedCentralGoogle Scholar
  76. 76.
    Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16.Google Scholar
  77. 77.
    Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 2010;15.Google Scholar
  78. 78.
    Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother. 2013;68:1267–70.CrossRefPubMedGoogle Scholar
  79. 79.
    Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to Cefixime in Toronto, Canada. JAMA. 2013;309:163–70. American Medical AssociationCrossRefPubMedGoogle Scholar
  80. 80.
    Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, O’Connor NP, et al. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA. Emerg Infect Dis. 2017;23:830–2. Centers for Disease Control and PreventionCrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    CDC. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR. 2007;56:332–6.Google Scholar
  82. 82.
    Savaris RF, Teixeira LM, Torres TG, Edelweiss MIA, Moncada J, Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease. Obstet Gynecol. 2007;110:53–60.CrossRefPubMedGoogle Scholar
  83. 83.
    Bevan C, Ridgway G, Rothermel C. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003;31:45–54.CrossRefPubMedGoogle Scholar
  84. 84.
    Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol. 2002;186:929–37.CrossRefPubMedGoogle Scholar
  85. 85.
    Savaris RF, Fuhrich DG, Duarte R V, Franik S, Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev. John Wiley & Sons, Ltd; 2017.Google Scholar
  86. 86.
    Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, et al. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database Syst Rev. John Wiley & Sons, Ltd; 2012.Google Scholar
  87. 87.
    Liang Z, Chen Y-P, Yang C-S, Guo W, Jiang X-X, Xu X-F, et al. Meta-analysis of ceftriaxone compared with penicillin for the treatment of syphilis. Int J Antimicrob Agents. 2016;47:6–11.CrossRefPubMedGoogle Scholar
  88. 88.
    Liu H, Han Y, Chen X, Bai L, Guo S, Li L, et al. Comparison of efficacy of treatments for early syphilis: a systematic review and network meta-analysis of randomized controlled trials and observational studies. PLoS One. 2017;12:e0180001. De Socio GV, editorCrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis. 2012;39:794–8.Google Scholar
  90. 90.
    Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351:154–8. Massachusetts Medical SocietyCrossRefPubMedGoogle Scholar
  91. 91.
    Walker GJ, JA G. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev. 2001.Google Scholar
  92. 92.
    Yang C-J, Lee N-Y, Chen T-C, Lin Y-H, Liang S-H, Lu P-L, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One. 2014;9:e109667. Public Library of ScienceCrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Ganesan A, Mesner O, Okulicz JF, O’Bryan T, Deiss RG, Lalani T, et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis. 2015;60:653–60.CrossRefPubMedGoogle Scholar
  94. 94.
    Jinno S, Anker B, Kaur P, Bristow CC, Klausner JD. Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging era of universal antiretroviral therapy use. BMC Infect Dis. 2013;13:605.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Tsai J-C, Lin Y-H, Lu P-L, Shen N-J, Yang C-J, Lee N-Y, et al. Comparison of serological response to doxycycline versus benzathine penicillin G in the treatment of early syphilis in HIV-infected patients: a multi-center observational study. PLoS One. 2014;9:e109813. Speck RF, editorCrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Lawrence D, Cresswell F, Whetham J, Fisher M. Syphilis treatment in the presence of HIV. Curr Opin Infect Dis. 2015;28:1.CrossRefGoogle Scholar
  97. 97.
    Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev. 2013.Google Scholar
  98. 98.
    Gottlieb SL, Johnston C. Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis. 2017;30:77–86. Wolters Kluwer HealthPubMedPubMedCentralGoogle Scholar
  99. 99.
    Kirkcaldy RD, Weinstock HS, Moore PC, Philip SS, Wiesenfeld HC, Papp JR, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59:1083–91.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Emergency MedicineMetroHealth Medical CenterClevelandUSA

Personalised recommendations